New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
05:47 EDTAGIOAgios Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Agios Pharmaceuticals to Overweight citing a declined risk profile following the company's "robust" interim phase 1 data on AG-221. The firm raised its price target for shares to $55 from $40.
News For AGIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
08:40 EDTAGIOAgios Pharmaceuticals initiates Phase 1/2 clinical trial of AG-221
Subscribe for More Information
07:06 EDTAGIOFierce Biotech to hold a breakfast meeting
Subscribe for More Information
October 15, 2014
07:40 EDTAGIOAgios Pharmaceuticals initiates four expansion cohorts in AG-221 Phase 1 study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use